A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : PD-L1

Search Conditions:
Search Keyword : PD-L1
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: PD-L1
Appearance Frequency: 3105 time(s)
Long forms: 32

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
programmed death-ligand 1
(2817 times)
Neoplasms
(1255 times)
PD-1 (753 times)
NSCLC (417 times)
OS (287 times)
0 [Checkpoint Inhibitors in the Treatment of Upper Gastrointestinal Tract Tumors].
PD-1 ligand
(218 times)
Neoplasms
(85 times)
PD-1 (154 times)
CTLA-4 (27 times)
NSCLC (19 times)
2001 Laser capture microdissection-based expression profiling identifies PD1-ligand as a target of the nude locus gene product.
protein ligand 1
(28 times)
Neoplasms
(12 times)
NSCLC (8 times)
CTLA-4 (3 times)
IHC (3 times)
2017 Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.
PD-1 and its ligand
(7 times)
Neoplasms
(2 times)
PD-1 (2 times)
Abs (1 time)
HBV (1 time)
2007 Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection.
programmed cell death-1 and its ligand-1
(5 times)
Neoplasms
(3 times)
BC (1 time)
CC (1 time)
CCA (1 time)
2016 Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC).
programmed death receptor-1 and its ligand
(3 times)
Neoplasms
(1 time)
NSCLC (1 time)
OSA (1 time)
SLN (1 time)
2014 Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line.
anti-PD-ligand-1
(2 times)
Neoplasms
(1 time)
PD-1 (2 times)
CTLA-4 (1 time)
Ig (1 time)
2017 Biomarkers to predict prognosis and response to checkpoint inhibitors.
1-PD-1-ligand
(1 time)
Biology
(1 time)
APCs (1 time)
CTLA-4 (1 time)
PD (1 time)
2003 T cell costimulatory pathways: blockade for autoimmunity.
PD-1 and its 2 B7 family ligands, B7-H1
(1 time)
Hematology
(1 time)
CTLs (1 time)
HA (1 time)
2007 Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.
10  PD-1 engagement to its ligand
(1 time)
Medicine
(1 time)
CMV (1 time)
PD-1 (1 time)
2006 Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction.
11  PD-1 ligand expression
(1 time)
Immunotherapy
(1 time)
CTLA-4 (1 time)
PD-1 (1 time)
SITC (1 time)
2016 Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
12  PD-1 ligand-positive T cells
(1 time)
Allergy and Immunology
(1 time)
IFN (1 time)
IL (1 time)
MTB (1 time)
2017 Programmed death-1+ T cells inhibit effector T cells at the pathological site of miliary tuberculosis.
13  PD-1 on CD4+CD25+ Tregs, CD19+ cells and its ligand
(1 time)
Allergy and Immunology
(1 time)
BI (1 time)
2017 Increased IL-35 producing Tregs and CD19+IL-35+ cells are associated with disease progression in leprosy patients.
14  PD-1 on Tcells and its ligand
(1 time)
Biological Science Disciplines
(1 time)
APCs (1 time)
2018 Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells.
15  PD-1 on Tregs, B cell and its ligand
(1 time)
Allergy and Immunology
(1 time)
BI (1 time)
2017 Increased IL-35 producing Tregs and CD19+IL-35+ cells are associated with disease progression in leprosy patients.
16  PD-1 receptor ligand
(1 time)
Immune System Diseases
(1 time)
PD-1 (1 time)
2014 Autoimmunity as a double agent in tumor killing and cancer promotion.
17  PD-1, namely, B7-H1
(1 time)
Allergy and Immunology
(1 time)
DCs (1 time)
PD-1 (1 time)
2002 Expression of programmed death 1 ligands by murine T cells and APC.
18  PD-1, the ligand of which
(1 time)
Antineoplastic Agents
(1 time)
PD-1 (1 time)
2019 Improved outcomes with pembrolizumab treatment in two cases of double cancer including non-small-cell lung cancer.
19  PD-1-PD-ligand 1
(1 time)
Allergy and Immunology
(1 time)
IFN (1 time)
IL (1 time)
MTB (1 time)
2017 Programmed death-1+ T cells inhibit effector T cells at the pathological site of miliary tuberculosis.
20  PD-L1 and TGF-beta than patients with advanced invasive thymic carcinoma
(1 time)
OS (1 time)
PFS (1 time)
TETs (1 time)
2018 Impact of PD-L1, transforming growth factor-beta expression and tumor-infiltrating CD8+ T cells on clinical outcome of patients with advanced thymic epithelial tumors.
21  PD-L1 and, more recently, chromosomal 9p24.1/CD274
(1 time)
Pathology
(1 time)
FISH (1 time)
IHC (1 time)
PD-L2 (1 time)
2018 Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
22  PD-L1 IHC
(1 time)
Pathology
(1 time)
NSCLC (1 time)
2016 [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
23  PD-L1 protein expression using two IHC assays, mRNA
(1 time)
Genetics, Medical
(1 time)
NSCLC (1 time)
2019 PD-L1 gene copy number and promoter polymorphisms regulate PD-L1 expression in tumor cells of non-small cell lung cancer patients.
24  PD-L1High
(1 time)
Molecular Biology
(1 time)
ALDH (1 time)
PD-1 (1 time)
TNBCs (1 time)
2019 WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.
25  plasma cells, are CD19-negative, and express B7-H1
(1 time)
Hematology
(1 time)
MM (1 time)
2010 A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients.
26  production of T cells via interaction with its ligands, B7-H1
(1 time)
Allergy and Immunology
(1 time)
--- 2014 Negative role of inducible PD-1 on survival of activated dendritic cells.
27  programmed cell death 1
(1 time)
Molecular Biology
(1 time)
--- 2018 Mouse-Derived Gastric Organoid and Immune Cell Co-culture for the Study of the Tumor Microenvironment.
28  programmed cell death ligand 1 antibody
(1 time)
Biomedical Engineering
(1 time)
Treg (1 time)
2019 Regulatory T Cells Tailored with pH-Responsive Liposomes Shape an Immuno-Antitumor Milieu against Tumors.
29  programmed cell death receptor-1
(1 time)
Allergy and Immunology
(1 time)
DCs (1 time)
LPS (1 time)
MSCs (1 time)
2017 Mesenchymal Stem Cells Upregulate the Expression of PD-L1 But Not VDR in Dendritic Cells.
30  Programmed Death Cell Ligand 1
(1 time)
Vascular Diseases
(1 time)
OS (1 time)
TIMs (1 time)
2017 Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
31  programmed death ligand 1 receptor
(1 time)
General Surgery
(1 time)
AR (1 time)
DFS (1 time)
EGFR (1 time)
2019 Prognostic markers in salivary gland cancer and their impact on survival.
32  programmed death-1 molecule ligand 1
(1 time)
Allergy and Immunology
(1 time)
CVID (1 time)
HLA-DR (1 time)
Ig (1 time)
2012 Monocyte activation is a feature of common variable immunodeficiency irrespective of plasma lipopolysaccharide levels.